11 maj 2026 Sweden
In an interview with BioStock, Sofia Mayans, Head of Manufacturing Site at Diamyd Medical, commented on the positive feedback received from the Swedish Medical Products Agency after an inspection of the company’s Umeå facility. The inspection brings Diamyd Medical closer to GMP certification and a manufacturing license for its recombinant protein platform. The company also sees potential future opportunities in partnerships, CDMO services, and licensing. Read the article here
|
4 maj 2026 Sweden
Diamyd Medical’s new CEO and company founder Anders Essen-Möller outlines next steps, including ongoing evaluations of partnerships and future development plans. Read the article here
|
27 april 2026 Sweden
Diamyd Medical’s CEO Anders Essen-Möller, comments on the company’s updates. Viewers are welcome to submit questions via the chat.
|
16 april 2026 Sweden
Diamyd Medical’s CEO Ulf Hannelius answers viewers' question on the strategic alternatives now being evaluated for the company's future.
Produced in collaboration with Biostock and moderated by Cecilia Hallström. Read the article/watch video here
|
30 mars 2026 Sweden
Maria Karlsson Osipova - analyst at DNB Carnegie, interviews Diamyd Medical CEO Ulf Hannelius and board member Mark Atkinson, and Joshua Vieth, BreakthroughT1D, following the DIAGNODE-3 interim readout.
|